Passage Bio Inc (PASG) — Strategic Asset Allocation Index
Passage Bio Inc (PASG) has a Strategic Asset Allocation Index of 13.4% as of June 2023. Strategic assets (PP&E of $20.23 Million plus long-term investments of $-) total $20.23 Million, measured against net assets of $150.41 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. For live market cap and overall valuation, see PASG market cap overview.
SAAI
Strategic Assets
PP&E
Net Assets
Passage Bio Inc Strategic Asset Allocation Index (2019–2022)
This chart shows how Passage Bio Inc's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of June 2023, the index stands at 13.4%, representing strategic assets of $20.23 Million against net assets of $150.41 Million USD. See PASG net asset quality index to measure how much of total assets are equity-financed.
Annual Strategic Asset Allocation Index for Passage Bio Inc (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Passage Bio Inc from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. Also explore Passage Bio Inc (PASG) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 11.2% | $22.52 Million | $22.52 Million | $- | $201.37 Million | ▲ +3.7 pp |
| 2021 | 7.5% | $23.81 Million | $23.81 Million | $- | $318.66 Million | ▲ +6.6 pp |
| 2020 | 0.9% | $2.79 Million | $2.79 Million | $- | $304.71 Million | ▲ +0.3 pp |
| 2019 | 0.6% | $1.09 Million | $1.09 Million | $- | $174.35 Million | — |